ArticlePloS one2011
Plasma membrane factor XIIIA transglutaminase activity regulates osteoblast matrix secretion and deposition by affecting microtubule dynamics.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 56 citations in OpenAlex.
- Establishing the reference intervals of plasma PLG, FXII activity, and FXIII antigen in healthy adults in Guangzhou.BMC cardiovascular disorders · 2025Article
- The Effect of Activated FXIII, a Transglutaminase, on Vascular Smooth Muscle Cells.International journal of molecular sciences · 2022Article
- MACF1 promotes osteoblast differentiation by sequestering repressors in cytoplasm.Cell death and differentiation · 2021Article
- Transglutaminases and Obesity in Humans: Association ofInternational journal of molecular sciences · 2020Article
- Proteolytic and nonproteolytic activation mechanisms result in conformationally and functionally different forms of coagulation factor XIII A.The FEBS journal · 2020Article
- Cellular Factor XIII, a Transglutaminase in Human Corneal Keratocytes.International journal of molecular sciences · 2019Article
- Thromboinflammation as bioactivity assessment of HJournal of materials science. Materials in medicine · 2019Article
- A small molecule regulator of tissue transglutaminase conformation inhibits the malignant phenotype of cancer cells.Oncotarget · 2018Article
- Transglutaminase activity regulates differentiation, migration and fusion of osteoclasts via affecting actin dynamics.Journal of cellular physiology · 2018Article
- Transglutaminases factor XIII-A and TG2 regulate resorption, adipogenesis and plasma fibronectin homeostasis in bone and bone marrow.Cell death and differentiation · 2017Article
- The complex role of transglutaminase 2 in glioblastoma proliferation.Neuro-oncology · 2017Article
- Advances of Coagulation Factor XIII.Chinese medical journal · 2017Review
- Factor XIII-A transglutaminase deficient mice show signs of metabolically healthy obesity on high fat diet.Scientific reports · 2016Article
- Interplay between transglutaminases and heparan sulphate in progressive renal scarring.Scientific reports · 2016Article
- Glu-tubulin is a marker for Schwann cells and can distinguish between schwannomas and neurofibromas.Histochemistry and cell biology · 2016Article
- Protein cross-linking by chlorinated polyamines and transglutamylation stabilizes neutrophil extracellular traps.Cell death & disease · 2016Article
- Article
- Cellular Factor XIIIA Transglutaminase Localizes in Caveolae and Regulates Caveolin-1 Phosphorylation, Homo-oligomerization and c-Src Signaling in Osteoblasts.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2015Article
- Decreased Mechanical Strength and Collagen Content in SPARC-Null Periodontal Ligament Is Reversed by Inhibition of Transglutaminase Activity.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2015Article
- Type II transglutaminase stimulates epidermal cancer stem cell epithelial-mesenchymal transition.Oncotarget · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Transglutaminase activity, arising potentially from transglutaminase 2 (TG2) and Factor XIIIA (FXIIIA), has been linked to osteoblast differentiation where it is required for type I collagen and fibronectin matrix deposition. In this study we have used an irreversible TG-inhibitor to 'block -and-track' enzyme(s) targeted during osteoblast differentiation. We show that the irreversible TG-inhibitor is highly potent in inhibiting osteoblast differentiation and mineralization and reduces secretion of both fibronectin and type I collagen and their release from the cell surface. Tracking of the dansyl probe by Western blotting and immunofluorescence microscopy demonstrated that the inhibitor targets plasma membrane-associated FXIIIA. TG2 appears not to contribute to crosslinking activity on the osteoblast surface. Inhibition of FXIIIA with NC9 resulted in defective secretory vesicle delivery to the plasma membrane which was attributable to a disorganized microtubule network and decreased microtubule association with the plasma membrane. NC9 inhibition of FXIIIA resulted in destabilization of microtubules as assessed by cellular Glu-tubulin levels. Furthermore, NC9 blocked modification of Glu-tubulin into 150 kDa high-molecular weight Glu-tubulin form which was specifically localized to the plasma membrane. FXIIIA enzyme and its crosslinking activity were colocalized with plasma membrane-associated tubulin, and thus, it appears that FXIIIA crosslinking activity is directed towards stabilizing the interaction of microtubules with the plasma membrane. Our work provides the first mechanistic cues as to how transglutaminase activity could affect protein secretion and matrix deposition in osteoblasts and suggests a novel function for plasma membrane FXIIIA in microtubule dynamics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.